MoonLake jumps as AbbVie's weak skin drug data eases competition fears

By Reuters News

** Shares of MoonLake Immunotherapeutics MLTX.O rise 21.7% to $12.96

** Rally follows AbbVie's ABBV.N late-stage trial data for its skin disease drug lutikizumab, which showed a modest 8% placebo-adjusted improvement in patients with hidradenitis suppurativa (HS)

** MoonLake is developing sonelokimab, a dual IL-17A/F inhibitor targeting the same chronic inflammatory skin condition

** Wedbush analyst Yun Zhong says the "underwhelming" AbbVie data supports sonelokimab as a "better treatment approach" and notes the rally reflects the "relief of an overhang of potential competition"

** Cantor analysts say "for MLTX, this is obviously a near-term positive given the potential reduced competitive threat" from AbbVie's drug

** Including session's moves, MLTX down 1.6% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.